ITOVEBI + IBRANCE + FASLODEX
A combination of inavolisib (Genentech), palbociclib (Genentech), and fulvestrant (AstraZeneca) for PIK3CA-altered hormone receptor–positive breast cancer.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and ITOVEBI + IBRANCE + FASLODEX. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where ITOVEBI + IBRANCE + FASLODEX is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Breast Cancer Solid Tumor · Breast | PIK3CA
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ITOVEBI + IBRANCE + FASLODEX.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ITOVEBI + IBRANCE + FASLODEX for eligible patients.